Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C20H26N2O2.BrH |
Molecular Weight | 407.345 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Br.[H][C@]1(C[C@@H]2CCN1C[C@@H]2CC)[C@H](O)C3=C4C=C(OC)C=CC4=NC=C3
InChI
InChIKey=BKKQYYLUFOIOJF-DSXUQNDKSA-N
InChI=1S/C20H26N2O2.BrH/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18;/h4-6,8,11,13-14,19-20,23H,3,7,9-10,12H2,1-2H3;1H/t13-,14-,19-,20+;/m0./s1
Molecular Formula | C20H26N2O2 |
Molecular Weight | 326.4326 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | BrH |
Molecular Weight | 80.912 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment: Description was created based on several sources, including https://www.drugs.com/international/hydroquinine.html
http://www.genome.jp/dbget-bin/www_bget?dr:D08265
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/international/hydroquinine.html
http://www.genome.jp/dbget-bin/www_bget?dr:D08265
Hydroquinine (Inhibin®) has been approved for marketing in the Netherlands for the treatment of nocturnal cramps when treatment with drugs is considered necessary. It is available in the Netherlands since March 1990 as an over-the-counter drug with a dose of 200 mg with the evening meal and a further 100 mg at bedtime for 14 days. Hydroquinine also has antimalarial and demelanizing activity. It might be used to lightens light brown color patches on skin, age spots, skin discolorations associated with pregnancy, skin trauma or taking birth control pills. Hydroquinine is used in skin lightening creams and lotions because it is an effective bleaching agent, slowing the production of the tyrosinase enzyme and reducing the amount of melanin formed.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL364 |
129.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Inhibin Approved UseHydroquinine hydrobromide (Inhibin®) has been approved for marketing in the
Netherlands for the treatment of nocturnal cramps when treatment with drugs is
considered necessary. Launch Date1990 |
|||
Curative | Unknown Approved UseUnknown |
|||
Primary | Hydroquinine Approved UseHydroquinine is used for the treatment, control, prevention, and improvement of the following diseases, conditions and symptoms:
Lightens light brown color patches on skin
Age spots
Skin discolorations associated with pregnancy
Skin trauma
Birth control pills
Hormone replacement therapy during menopause |
Sample Use Guides
200 mg with the evening meal and a further 100 mg at bedtime for 14 days
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8944272
The median inhibitory concentration (IC50) for hydroquinine against Plasmodium falciparum in vitro was 129 nmol/L (range 54-324)
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:24:10 GMT 2023
by
admin
on
Fri Dec 15 15:24:10 GMT 2023
|
Record UNII |
Q26K81T6MC
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
21125220
Created by
admin on Fri Dec 15 15:24:11 GMT 2023 , Edited by admin on Fri Dec 15 15:24:11 GMT 2023
|
PRIMARY | |||
|
100000077620
Created by
admin on Fri Dec 15 15:24:11 GMT 2023 , Edited by admin on Fri Dec 15 15:24:11 GMT 2023
|
PRIMARY | |||
|
Q26K81T6MC
Created by
admin on Fri Dec 15 15:24:11 GMT 2023 , Edited by admin on Fri Dec 15 15:24:11 GMT 2023
|
PRIMARY | |||
|
85153-19-1
Created by
admin on Fri Dec 15 15:24:10 GMT 2023 , Edited by admin on Fri Dec 15 15:24:10 GMT 2023
|
PRIMARY | |||
|
SUB14139MIG
Created by
admin on Fri Dec 15 15:24:10 GMT 2023 , Edited by admin on Fri Dec 15 15:24:10 GMT 2023
|
PRIMARY | |||
|
SUB36265
Created by
admin on Fri Dec 15 15:24:10 GMT 2023 , Edited by admin on Fri Dec 15 15:24:10 GMT 2023
|
ALTERNATIVE | |||
|
DTXSID901005573
Created by
admin on Fri Dec 15 15:24:10 GMT 2023 , Edited by admin on Fri Dec 15 15:24:10 GMT 2023
|
PRIMARY | |||
|
285-797-5
Created by
admin on Fri Dec 15 15:24:10 GMT 2023 , Edited by admin on Fri Dec 15 15:24:10 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |